Daiichi Sankyo announced that Enhertu (trastuzumab deruxtecan) has been approved in Japan for the treatment of adult patients with HER2 positive unresectable or recurrent breast cancer after prior chemotherapy, which includes trastuzumab and a taxane.
The approval by Japan
